Skip to main content
Erschienen in: Journal of General Internal Medicine 6/2019

18.03.2019 | Clinical Practice: Clinical Vignettes

A Patient with Sjogren’s Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis

verfasst von: Jason Hom, MD, Shruti Marwaha, PhD, Anna Postolova, MD, Jessie Kittle, MD, Rosaline Vasquez, MD, Jean Davidson, PhD, Jennefer Kohler, MS, LCGC, Annika Dries, BS, Liliana Fernandez-Betancourt, MD, Marta Majcherska, BS, Joanna Dearlove, MD, Shyam Raghavan, MD, Hannes Vogel, MD, PhD, Jonathan A. Bernstein, MD, PhD, Paul Fisher, MD, Euan Ashley, MRCP, PhD, Jacinda Sampson, MD, PhD, Matthew Wheeler, MD, PhD, Undiagnosed Diseases Network

Erschienen in: Journal of General Internal Medicine | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

We discuss a challenging case of a 58-year-old Vietnamese-American woman who presented to her new primary care provider with an 8-year history of slowly progressive dysphagia, hoarseness, muscle weakness with associated frequent falls, and weight loss. She eventually reported dry eyes and dry mouth, and she was diagnosed with Sjogren’s syndrome. Subsequently, she was additionally diagnosed with inclusion body myositis and gastric light-chain (AL) amyloidosis. Although inclusion body myositis has been previously associated with Sjogren’s syndrome, inclusion body myositis is rare in non-Caucasians, and the trio of Sjogren’s syndrome, inclusion body myositis, and AL amyloidosis has not been previously reported. Sjogren’s syndrome is a systemic autoimmune condition characterized by ocular and oral dryness. It is one of the most common rheumatologic disorders in the USA and worldwide. Early diagnosis of Sjogren’s is particularly important given the frequency and variety of associated autoimmune diseases and extraglandular manifestations. Furthermore, although inclusion body myositis has a low prevalence, it is the most common inflammatory myopathy in older adults and is unfortunately associated with long delays in diagnosis, so knowledge of this disorder is also crucial for practicing internists.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Gahl WA, Wise AL, Ashley EA. The Undiagnosed Diseases Network of the National Institutes of Health: A National Extension. JAMA, 2015;314(17):1797–8CrossRefPubMed Gahl WA, Wise AL, Ashley EA. The Undiagnosed Diseases Network of the National Institutes of Health: A National Extension. JAMA, 2015;314(17):1797–8CrossRefPubMed
2.
Zurück zum Zitat Kanellopoulos P, Baltoyiannis C, Tzioufas AG. Primary Sjogren’s syndrome associated with inclusion body myositis. Rheumatology (Oxford), 2002;41(4):440–4CrossRef Kanellopoulos P, Baltoyiannis C, Tzioufas AG. Primary Sjogren’s syndrome associated with inclusion body myositis. Rheumatology (Oxford), 2002;41(4):440–4CrossRef
3.
Zurück zum Zitat Rojana-udomsart A, et al.The association of sporadic inclusion body myositis and Sjogren’s syndrome in carriers of HLA-DR3 and the 8.1 MHC ancestral haplotype. Clin Neurol Neurosurg. 2011;113(7):559–63CrossRefPubMed Rojana-udomsart A, et al.The association of sporadic inclusion body myositis and Sjogren’s syndrome in carriers of HLA-DR3 and the 8.1 MHC ancestral haplotype. Clin Neurol Neurosurg. 2011;113(7):559–63CrossRefPubMed
4.
Zurück zum Zitat Perlat A, et al. Systemic light chain amyloidosis and Sjogren syndrome: an uncommon association. In: Amyloid. England; 2009:181–2 Perlat A, et al. Systemic light chain amyloidosis and Sjogren syndrome: an uncommon association. In: Amyloid. England; 2009:181–2
5.
Zurück zum Zitat Dalakas MC, et al. Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol. 1997;41(1):100–4CrossRefPubMed Dalakas MC, et al. Inclusion body myositis and paraproteinemia: incidence and immunopathologic correlations. Ann Neurol. 1997;41(1):100–4CrossRefPubMed
7.
Zurück zum Zitat Cruz-Tapias P, et al. HLA and Sjogren’s syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev. 2012;11(4):281–7CrossRefPubMed Cruz-Tapias P, et al. HLA and Sjogren’s syndrome susceptibility. A meta-analysis of worldwide studies. Autoimmun Rev. 2012;11(4):281–7CrossRefPubMed
8.
Zurück zum Zitat Badrising UA, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology. 2004;63(12):2396–8CrossRefPubMed Badrising UA, et al. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology. 2004;63(12):2396–8CrossRefPubMed
9.
Zurück zum Zitat Misterska-Skora M, et al. Inclusion body myositis associated with Sjogren’s syndrome. Rheumatol Int. 2013;33(12):3083–6CrossRefPubMed Misterska-Skora M, et al. Inclusion body myositis associated with Sjogren’s syndrome. Rheumatol Int. 2013;33(12):3083–6CrossRefPubMed
10.
Zurück zum Zitat Benveniste O, et al. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol. 2015;129(5): p. 611–24CrossRefPubMedPubMedCentral Benveniste O, et al. Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken. Acta Neuropathol. 2015;129(5): p. 611–24CrossRefPubMedPubMedCentral
11.
13.
Zurück zum Zitat Cox FM, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134(Pt 11):3167–75CrossRefPubMed Cox FM, et al. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134(Pt 11):3167–75CrossRefPubMed
14.
Zurück zum Zitat Benveniste O, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134(Pt 11):3176–84CrossRefPubMed Benveniste O, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134(Pt 11):3176–84CrossRefPubMed
15.
Zurück zum Zitat Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve. 2000;23(6):970–2CrossRefPubMed Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve. 2000;23(6):970–2CrossRefPubMed
16.
Zurück zum Zitat Voermans NC, et al. Primary respiratory failure in inclusion body myositis. Neurology. 2004;63(11):2191–2CrossRefPubMed Voermans NC, et al. Primary respiratory failure in inclusion body myositis. Neurology. 2004;63(11):2191–2CrossRefPubMed
17.
Zurück zum Zitat Graber ML, Mathew A. Performance of a web-based clinical diagnosis support system for internists. J Gen Intern Med. 2008;23 Suppl 1:37–40CrossRefPubMed Graber ML, Mathew A. Performance of a web-based clinical diagnosis support system for internists. J Gen Intern Med. 2008;23 Suppl 1:37–40CrossRefPubMed
18.
Zurück zum Zitat Bond WF, et al. Differential diagnosis generators: an evaluation of currently available computer programs. J Gen Intern Med. 2012;27(2):213–9CrossRefPubMed Bond WF, et al. Differential diagnosis generators: an evaluation of currently available computer programs. J Gen Intern Med. 2012;27(2):213–9CrossRefPubMed
19.
Zurück zum Zitat Riches N, et al. The Effectiveness of Electronic Differential Diagnoses (DDX) Generators: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(3):e0148991CrossRefPubMedPubMedCentral Riches N, et al. The Effectiveness of Electronic Differential Diagnoses (DDX) Generators: A Systematic Review and Meta-Analysis. PLoS One. 2016;11(3):e0148991CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Derk CT, et al. Inclusion body myositis in connective tissue disorders: case report and review of the literature. Clin Rheumatol. 2003;22(4–5):324–8CrossRefPubMed Derk CT, et al. Inclusion body myositis in connective tissue disorders: case report and review of the literature. Clin Rheumatol. 2003;22(4–5):324–8CrossRefPubMed
21.
Zurück zum Zitat Schrey A, et al. Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. J Neurol Sci. 2017;380:142–147CrossRefPubMed Schrey A, et al. Botulinum toxin alleviates dysphagia of patients with inclusion body myositis. J Neurol Sci. 2017;380:142–147CrossRefPubMed
22.
23.
Zurück zum Zitat Mingueneau M, et al. Cytometry by time-of-flight immunophenotyping identifies a blood Sjogren’s signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol. 2016;137(6):1809–1821.e12CrossRefPubMed Mingueneau M, et al. Cytometry by time-of-flight immunophenotyping identifies a blood Sjogren’s signature correlating with disease activity and glandular inflammation. J Allergy Clin Immunol. 2016;137(6):1809–1821.e12CrossRefPubMed
24.
Zurück zum Zitat Renaudineau Y. Immunophenotyping As a New Tool for Classification and Monitoring of Systemic Autoimmune Diseases. Clin Rev Allergy Immunol. 2017;53(2):177–180CrossRefPubMed Renaudineau Y. Immunophenotyping As a New Tool for Classification and Monitoring of Systemic Autoimmune Diseases. Clin Rev Allergy Immunol. 2017;53(2):177–180CrossRefPubMed
Metadaten
Titel
A Patient with Sjogren’s Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis
verfasst von
Jason Hom, MD
Shruti Marwaha, PhD
Anna Postolova, MD
Jessie Kittle, MD
Rosaline Vasquez, MD
Jean Davidson, PhD
Jennefer Kohler, MS, LCGC
Annika Dries, BS
Liliana Fernandez-Betancourt, MD
Marta Majcherska, BS
Joanna Dearlove, MD
Shyam Raghavan, MD
Hannes Vogel, MD, PhD
Jonathan A. Bernstein, MD, PhD
Paul Fisher, MD
Euan Ashley, MRCP, PhD
Jacinda Sampson, MD, PhD
Matthew Wheeler, MD, PhD
Undiagnosed Diseases Network
Publikationsdatum
18.03.2019
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 6/2019
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-04931-w

Weitere Artikel der Ausgabe 6/2019

Journal of General Internal Medicine 6/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.